Navigation Links
Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of soluble CD83 at the 7th Joint American Transplant meeting to be held in San Francisco, May 5-9. The presentations will be made in collaboration with scientists at the University of Western Ontario.

"These data suggest that soluble CD83 is able to extend graft survival in transplantation, and that it can also act synergistically with other immunosuppressive agents," commented Dr. Stephen Brand, Director of Biotherapeutics at Argos Therapeutics. "sCD83 appears to be able to maintain antigen presenting cells in an immature state, and these immunologically tolerant cells favor regulatory T-cell generation because they are less effective in activating naive T and B cells."

"This emerging activity profile for sCD83, as well as its ability to suppress antibody production without systemic suppression, may provide advantages over currently available B-cell targeting therapies," said Dr. Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development of Argos. "The extended graft survival that we have observed thus far indicates that sCD83 could potentially provide enhanced organ function, without immune rejection, and may serve to reduce the toxic profile associated with many commonly used immunotherapeutic agents. These data support Argos' plans to conduct additional studies with CD83 in transplantation and autoimmune models, which will provide important information as we develop a clinical strategy for this candidate."

Data will be discussed in the following presentations:

-- Abstract # 1697: "Soluble CD83 in combination with Rapamycin and anti-CD45RB monoclonal antibody induces long-term graft survival in a mouse cardiac transplantation model"

-- Abstract #116: "Soluble CD83 can inhibit B-cell activation and differentiati on"

-- Abstract #1035: "Immunosuppressive properties of soluble extracellular domain of CD83 on antigen-presenting cells of cynomologous monkey"

About Soluble CD83

CD83 is a glycoprotein expressed on the cell surface of mature dendritic cells (DCs), the most potent stimulators of immune responses. The strong upregulation of this protein during DC maturation suggests that it plays an important functional role in the induction of immune responses. Experimental data demonstrate that soluble CD83 can potently down-regulate immune responses, indicating that it can be developed to treat transplantation rejection and variety of autoimmune disorders. Importantly, data from animal models demonstrate that soluble CD83 exerts its effects without a requirement for chronic administration and does not leave the subject globally immunosuppressed. In April 2006, Argos obtained exclusive therapeutic use rights for CD83 from Beckman Coulter.

About Argos Therapeutics, Inc.

Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient's disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company's "Arcelis" technology, trains the immune system to recognize and attack the disease. Argos' scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com

Argos is a private biotechnology company headquartered in Research Triangle Park, NC. The Company has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company, Limited.

Contact

MacDougall Biomedical Communications
Chris Erdman, 508-647-0209
or
Argos Therapeutics
Jeff Abbey, 919-287-6308


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel ... thousand words. The good news for single women is that she put all the ... available on April 25th. Joan's insight, personal experiences and sparkling sense of humor have ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
Breaking Medicine News(10 mins):